TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Functional Performance Evaluation of NU-FlexSIV Socket

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* unilateral transfemoral amputation~* have used a prosthesis for two or more years~* have a residual limb that is stable in volume and free from wounds~* be physically fit enough to participate in the performance tests (Medicare Functional Classification Level K3 or K4)~* have no previous experience of the sub-ischial socket~* able to complete all visits for the duration of the protocol~Exclusion Criteria:~* have a residual limb femur of less than 5-inches~* co-morbidities that affect function, including neurologic abnormalities (e.g. neuropathic pain that would interfere with the study)~* do not speak and read English

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NU-FlexSIV Socket (Type: ACTIVE_COMPARATOR): The Northwestern University Flexible Sub-Ischial Vacuum Socket is a novel socket design for transfemoral amputees.
- IC Socket (Type: ACTIVE_COMPARATOR): The Ischial Containment Socket is the standard of care socket design for transfemoral amputees.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tele-Self CBTI Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets diagnostic criteria for Insomnia Disorder~* Receives care through the Durham VA Health Care System (HCS) catchment area~Exclusion Criteria:~* Severe Obstructive Sleep Apnea with treatment non-adherence~* Unstable co-morbid sleep disorder determined via chart review~  * e.g., rule out for Narcolepsy, rule out for Shift Work Disorder~* Current or prior participation in Cognitive Behavioral Therapy for Insomnia (CBTI)~* Excessive daytime sleepiness~* Nighttime or rotating shift work within the last year~* Psychotic disorder diagnosis~* Bipolar disorder diagnosis~* Recreational substance use~* Current alcohol abuse~* Severe depression or suicidality~* Dementia diagnosis~* Cognitive impairment~* Epilepsy diagnosis~* Seizure disorder diagnosis~* Lack of proficiency in the English language~* Hearing impairment that impedes telehealth intervention~* Unable to complete study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tele-Self CBTI (Type: EXPERIMENTAL): Tele-Self CBTi is a telephone-based CBT insomnia intervention
- Health Education Control (Type: ACTIVE_COMPARATOR): The Health Education is an active control arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese patients diagnosed with visual impairment exclusively due to macular edema secondary to either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) Diagnosis within 12 months prior to Visit 1~* Best-corrected visual acuity (BCVA):~* CRVO: BCVA score ≥24 and ≤73 letters ETDRS (approx. Snellen equivalent of 20/320 and 20/40) at Visit 1 and 2~* BRVO: BCVA score ≥19 and ≤73 letters ETDRS (approx. Snellen equivalent of 20/400 and 20/40) at Visit 1 and 2~Exclusion Criteria:~* Pregnant or nursing women~* History of stroke~* Uncontrolled blood pressure~* Active ocular infection or intraocular inflammation in either eye~* Uncontrolled glaucoma in either eye~* Neovascularization of the iris or neovascular glaucoma in either eye~* Prior episode of RVO more than 12 months prior to Visit 1 in the study eye~* Use of any systemic anti-VEGF drugs within 6 months prior to Visit 2~* Prior treatment with any anti-angiogenic drugs within 3 months prior to Visit 2 in either eye~* Prior panretinal laser photocoagulation within 3 months prior to Visit 2 in the study eye~* Prior focal/grid laser photocoagulation within 4 months prior to Visit 2 in the study eye~* Use of intra-/peri-ocular corticosteroids within 3 months prior to Visit 1 in the study eye~* Use of any intra-ocular corticosteroid implants in the study eye~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ranibizumab intravitreal injection (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA~* Newly-diagnosed with mantle cell lymphoma (MCL) with accessible disease site for excisional biopsy, OR have sufficient peripheral blood tumor to leukapherese ≥ 1.5 x 10e9 lymphoma cells in a single session~* Medically appropriate by standard clinical criteria to receive rituximab and standard induction chemotherapy and high-dose chemotherapy with autologous hematopoietic cell transplant (AHCT)~* HIV-negative~* Eastern Cooperative Oncology Group (ECOG) Performance Status, OR Karnofsky performance scale 50 to 100%~* Capable of providing informed consent~EXCLUSION CRITERIA~* Currently receiving immunosuppressive medications~* Severe psychological or medical illness~* Pregnant or lactating~* Unable to safely complete the study, at the discretion of the principal investigator

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CpG-MCL Vaccine (Type: EXPERIMENTAL): An autologous anti-tumor vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First post-transplant squamous cell carcinoma in a kidney transplant recipient under calcineurin inhibitors~Exclusion Criteria:~* Other squamous cell carcinomas in the past history~* More than 2 transplantations~* Patients not under calcineurin inhibitors~* Unstable graft function~* Non controlled hyperlipidemia (cholesterol \> 7.8 mmol/l or triglycerides \> 3.95 mmol/l)~* Leucopenia \< 3000/mm3~* Thrombocytopenia \< 100,000/mm3~* Liver dysfunction~* Pregnancy~* Allergy to macrolides

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): patients receiving Rapamycin
- 2 (Type: ACTIVE_COMPARATOR): patients receiving anticalcineurin treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Heart transplantation~* LVAD placement~* Lung Transplantation~Exclusion Criteria:~* Combined Organ Transplantation~* Age \< 18 years old~* Pregnancy~* Known allergy to prostaglandin (rare)~* Refusal of blood products due to personal or religious preference~* Subject is enrolled in another study protocol, which does not allow randomization of PVD therapy~* Heart transplant or durable LVAD recipients with adult congenital heart disease (CHD)~  o Caveat: Does NOT meet exclusion criteria if the scheduled heart transplant or LVAD implantation is due to heart failure from a previous heart transplantation related to CHD, performed more than 90 days previous to the date of trial enrollment~* Heart transplant recipients diagnosed with Arrythmogenic Right Ventricular Cardiomyopathy~* Heart transplant recipients diagnosed with Acute Cardiac Allograft Rejection after a previous heart transplantation.~* Heart transplant or durable LVAD recipients with preoperative RVAD for right heart failure~* Patient is scheduled to undergo lung transplantation but has undergone heart transplantation in the previous 90 days~* Patient is scheduled to undergo durable LVAD implantation but has undergone heart transplantation in the previous 90 days~* Patient is scheduled to undergo heart transplantation but has undergone lung transplantation in the previous 90 days~* Patients with preoperative Venovenous ECMO as a bridge to lung transplantation~* Heart transplant or durable LVAD recipients with preoperative RVAD for right heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lung transplant with iNO (Type: ACTIVE_COMPARATOR): None
- Lung transplant with iEPO (Type: ACTIVE_COMPARATOR): None
- Heart transplant & LVAD implantation with iNO (Type: ACTIVE_COMPARATOR): None
- Heart transplant & LVAD implantation with iEPO (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Aerosolised Colistin in Ventilator Associated Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Critically ill patients older than 18 years, with mechanical ventilation during more than 48 hours, and who have presented a Ventilator associated Pneumonia (VAP) defined as a CPIS (Clinical Pulmonary Infection Score) of more than six~Exclusion Criteria:~* Age \<18 years~* Pregnancy~* Septic shock

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- aerosolised (AS) colistin group (Type: ACTIVE_COMPARATOR): the intervention was: AS colistin and imipenem. the drug administered was colimycin (colistin) powder 1 million units (MU) by a flakon (Sanofi Winthrop Industry) at the dosage of 4 million units (MU) for 30 minutes 3 times per day for at least 14 days in addition to IV imipenem 1 g three times per day. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland). Inhaled colimycin® requires specific settings of the ventilator to limit turbulence inspiratory flow. The adjustment consisted in a volume controlled mode with a Tidal volume \<8 ml / kg, respiratory rate at 12 cycles / min, I / E: 1/1 and an end inspiratory break \> 20%.
- intravenous (IV) colistin goup (Type: ACTIVE_COMPARATOR): the intervention was: IV colistin and imipenem. the intravenous (IV) colistin goup received IV colimycin (colistin) as a loading dose of 9 MU during 60 minutes followed by 4.5 million units 2 times per day in addition to IV imipenem 1 g three times per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Propofol Cardioprotection for Type II Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with and without Type II Diabetes Mellitus~2. Hemodynamically Stable~3. Non urgent Coronary Bypass Grafting utilizing Cardiopulmonary Bypass~Exclusion Criteria:~1. Age less than 18 or greater than 80 years of age~2. refuse informed consent~3. Co-existing valvular heart disease~4. Acute or evolving myocardial infarction~5. hypersensitivity to propofol or formulation component~6. Use of NSAIDs, Vitamins C or E within 5 to 7 days of surgery

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 29 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Propofol Cardioprotection
- 2 (Type: EXPERIMENTAL): Volatile Anesthesia Preconditioning

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Homozygous (HbSS) Sickle Cell Anemia~* Otherwise healthy (based on medical history, physical examination, 12-lead ECG, and clinical laboratory tests)~* Patients may be receiving hydroxyurea, but must have been dose stabilized for at least 3 months~* Patient has a history of at least one acute vaso-occlusive event requiring hospitalization~Exclusion Criteria:~* Patient participating in a chronic transfusion program~* Patient having a total hemoglobin of \< 4.0 g/dL or \> 10.0 g/dL~* Patient having a HbA \> 10%~* Patient considering undergoing an elective surgery~* Patient taking prohibited medications such as Epoetin, Warfarin, etc.~* Patient who has had previous gastrointestinal surgery, except cholecystectomy or appendectomy~* Patient with significant active cardiovascular, neurologic, endocrine, hepatic, or renal disorders unrelated to sickle cell anemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- ICA-17043 Low Dose 6 mg/day (Type: EXPERIMENTAL): Active study medication: 100 mg loading dose; 6 mg maintenance dose per day
- Placebo (Type: PLACEBO_COMPARATOR): None
- ICA-17043 High Dose 10 mg/day (Type: EXPERIMENTAL): Active study medication: 150 mg loading dose; 10 mg maintenance dose per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine in the Treatment of Patients With Anorexia Nervosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* those who meet DSM IV criteria of Anorexia Nervosa- either restricting or binge/purge subtype~Exclusion Criteria:~* patients who are actively self destructive and/or suicidal~* patients whose medical status is seriously compromised~* patients whose eating disorder is superimposed on a major psychiatric disorder such as schizophrenia, major affective disorders, dissociative disorder or an active substance abuse disorder.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo and Treatment as usual (Day Hospital Program). After a 2-week baseline period, placebo was administered for 10 weeks (weeks 3-12 of the study). Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
- Olanzapine Plus Day Hospital (Type: EXPERIMENTAL): After a 2-week baseline period, Olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of 10 mg/day. Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 18-65.~* Subjects must have POTS diagnosis (Hyperadrenergic Subtype with NE\> 600pg/ml))~* Subjects with no structural heart disease~* Subject with no arrhythmias~* Subjects with norepinephrine levels greater than 600 pg/ml~* Subjects with normal CBC, Metabolic, and thyroid levels~Exclusion Criteria:~* Thyroid or adrenal disorders~* Drugs that interfere with Ivabradine (example: Cytochrome P450 drugs)~* Presentation of peripheral edema and discolored toes with peripheral autonomic neuropathy. Symptoms include: legs (reduced hair growth, cramps), toes (blue color), legs/feet (wounds, ulcers that do not heal), and muscles (numbness, heaviness)~* Subjects who have had a history of systemic illnesses (acute or chronic infectious); autoimmune/ inflammatory disease, cancer, COPD, anemia, diabetes, or psychiatric illness~* Subjects with resting heart rate\< 60beats/min, atrial fibrillation, advanced AV blocks, sinus disease, and acute decompensated heart failure and severe hepatic impairment.~* Smokers or alcohol abuse~* Pregnant or breastfeeding mothers~* Woman of childbearing potential who are unwilling to use highly effective contraception during treatment and for an additional one month after discontinuing the study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Patient will consume one placebo pill twice a day for one month.
- Ivabradine (Type: EXPERIMENTAL): Patient will consume one dose of Ivabradine twice a day for one month.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of ACE-536 in Healthy Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Postmenopausal women~* Body Mass Index (BMI) of 20 - 32 kg/m2.~Key Exclusion Criteria:~* History of hypertension~* Subject has received any erythropoiesis stimulating agents (e.g., Epogen, Procrit, Aranesp, etc.) within 6 months prior to Day 1~* History of clinically significant cardiac, endocrine, hematologic, hepatic, immune, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other disease~* Surgery within 3 months (other than minor cosmetic surgery or minor dental procedures)~* Subject has received treatment with another investigational drug, or approved therapy for investigational use within 1 month prior to Day 1, or if the half-life of the previous product is known, within 5 times the half-life prior to Day 1, whichever is longer

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- ACE-536 (Type: EXPERIMENTAL): Subjects assigned to 1 of 5 possible dosing groups.
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 years and above~* Gender eligible for study: both~* Hypertensive diabetic patients either previously diagnosed or newly found.~* Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 80 mmHg for newly found hypertensive patients.~* Fasting blood glucose ≥ 126 mg/dl or PP2 blood glucose ≥ 200 mg/dl for newly found diabetes.~* Patients with significant de novo coronary artery disease (diameter stenosis \> 70%) requiring stent implantation (angina pectoris and/or exercise-induced ischemia).~* Patients with informed consent.~Exclusion Criteria:~* Acute ST-segment elevation myocardial infarction (MI), CTO lesions, left main lesions~* Diabetic patients with the use of thiazolidinediones within 3 months~* Previous history of PCI or bypass surgery~* Patients with any contraindications to the treatment of telmisartan or valsartan~* Pregnant or lactating patients~* Chronic alcohol or drug abuse~* Hepatic dysfunction~* Renal dysfunction~* Heart failure (EF \< 50%)~* Expected life expectancy of \< 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete